









Markets
/
Stocks
/
nasdaq-xrtx
/

XORTX Therapeutics Inc

XRTX

View Detailed Chart

0.726USD

-0.013-1.83%

Market hours （ET）Quotes delayed by 15 min

2.75MMarket Cap

LossP/E TTM



XORTX Therapeutics Inc

0.726

-0.013-1.83%

Overview Company Financials

Financials

Intraday

30m

Today

-1.83%

5 Days

-13.11%

1 Month

-19.40%

6 Months

-18.97%

Year to Date

-35.77%

1 Year

-53.79%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

14.000

Target Price

1450.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

XORTX Therapeutics Inc

XRTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(10)

Neutral(1)

Buy(0)

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.040

Sell

RSI(14)

36.022

Neutral

STOCH(KDJ)(9,3,3)

13.352

Oversold

ATR(14)

0.068

Low Volatility

CCI(14)

-129.314

Sell

Williams %R

79.075

Sell

TRIX(12,20)

-0.488

Sell

StochRSI(14)

6.429

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.745

Sell

MA10

0.824

Sell

MA20

0.858

Sell

MA50

0.888

Sell

MA100

0.930

Sell

MA200

1.060

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Ticker SymbolXRTX

CompanyXORTX Therapeutics Inc

CEODr. Allen W. Davidoff, Ph.D.

Websitehttps://www.xortx.com/